Bifogade filer
Bulletin from the Extraordinary General Meeting of Flerie AB (publ) on 29 December 2025 at 11:00 CET
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
The Extraordinary General Meeting of Flerie AB (publ) reg. no. 559067-6820 (“Flerie” or the “Company”) has been held on 29 December 2025 at 11:00 CET, at which the following resolution were made.
Resolution to carry out a related-party transaction under Chapter 16a of the Swedish Companies Act
The Extraordinary General Meeting resolved to approve the Board of Directors proposal to transfer Flerie's investments in investment funds (the Limited Partnership segment) to T&M Participation AB, reg.no 556856-6623, owned by the Company’s Chairman of the Board of Directors, Thomas Eldered. The Meeting has resolved on the proposal in accordance with the rules regarding related-party transactions under Chapter 16a of the Swedish Companies Act (SFS 2005:551). Shares and votes that are, directly or indirectly, held by Thomas Eldered have not been taken into account when the Meeting resolved on the transfer of the Limited Partnership segment.
The Limited Partnership segment represents approximately 3 per cent of Flerie's net asset value. The transfer of the Limited Partnership segment will be made at fair value as of 31 December 2025. As of 30 November 2025, the value of the Limited Partnership segment amounted to approximately SEK 109 million, which is based on the funds' valuations as of the third quarter of 2025 and on exchange rates as of 30 November 2025. Valuations as of 31 December 2025 are expected to be received from the funds during the first quarter of 2026. The Meeting has resolved that the transaction be carried out based on the value in the NAV report as of 30 November 2025, after which a final settlement will be made in the first quarter of 2026 when the final valuations as of 31 December 2025 have been received from each fund manager.
The sale will be carried out in connection with the Extraordinary General Meeting, which means that Flerie receives approximately SEK 109 million in cash and that the Company’s outstanding commitments towards the funds will be reduced by approximately SEK 150 million.
For further information, please contact:
Ted Fjällman, CEO of Flerie
E-mail: ir@flerie.com
Telephone: +46 (0)76 600 89 26
The information was submitted for publication, through the agency of the contact person above, on 29 December 2025, at 11:30 CET.
About Flerie
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com.